Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services.


Journal

Psycho-oncology
ISSN: 1099-1611
Titre abrégé: Psychooncology
Pays: England
ID NLM: 9214524

Informations de publication

Date de publication:
05 2019
Historique:
received: 14 12 2018
revised: 21 02 2019
accepted: 25 02 2019
pubmed: 28 2 2019
medline: 18 12 2019
entrez: 28 2 2019
Statut: ppublish

Résumé

There is still lack of consensus on the benefit-harm balance of breast cancer screening. In this scenario, women's values and preferences are crucial for developing health-related recommendations. In the context of the European Commission Initiative on Breast Cancer, we conducted a systematic review to inform the European Breast Guidelines. We searched Medline and included primary studies assessing women's values and preferences regarding breast cancer screening and diagnosis decision making. We used a thematic approach to synthesise relevant data. The quality of evidence was determined with GRADE, including GRADE CERQual for qualitative research. We included 22 individual studies. Women were willing to accept the psychological and physical burden of breast cancer screening and a significant risk of overdiagnosis and false-positive mammography findings, in return for the benefit of earlier diagnosis. The anxiety engendered by the delay in getting results of diagnostic tests was highlighted as a significant burden, emphasising the need for rapid and efficient screening services, and clear and efficient communication. The confidence in the findings was low to moderate for screening and moderate for diagnosis, predominantly because of methodological limitations, lack of adequate understanding of the outcomes by participants, and indirectness. Women value more the possibility of an earlier diagnosis over the risks of a false-positive result or overdiagnosis. Concerns remain that women may not understand the concept of overdiagnosis. Women highly value time efficient screening processes and rapid result delivery and will accept some discomfort for the peace of mind screening may provide.

Sections du résumé

BACKGROUND
There is still lack of consensus on the benefit-harm balance of breast cancer screening. In this scenario, women's values and preferences are crucial for developing health-related recommendations. In the context of the European Commission Initiative on Breast Cancer, we conducted a systematic review to inform the European Breast Guidelines.
METHODS
We searched Medline and included primary studies assessing women's values and preferences regarding breast cancer screening and diagnosis decision making. We used a thematic approach to synthesise relevant data. The quality of evidence was determined with GRADE, including GRADE CERQual for qualitative research.
RESULTS
We included 22 individual studies. Women were willing to accept the psychological and physical burden of breast cancer screening and a significant risk of overdiagnosis and false-positive mammography findings, in return for the benefit of earlier diagnosis. The anxiety engendered by the delay in getting results of diagnostic tests was highlighted as a significant burden, emphasising the need for rapid and efficient screening services, and clear and efficient communication. The confidence in the findings was low to moderate for screening and moderate for diagnosis, predominantly because of methodological limitations, lack of adequate understanding of the outcomes by participants, and indirectness.
CONCLUSIONS
Women value more the possibility of an earlier diagnosis over the risks of a false-positive result or overdiagnosis. Concerns remain that women may not understand the concept of overdiagnosis. Women highly value time efficient screening processes and rapid result delivery and will accept some discomfort for the peace of mind screening may provide.

Identifiants

pubmed: 30812068
doi: 10.1002/pon.5041
pmc: PMC6594004
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

939-947

Informations de copyright

© 2019 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.

Références

Appl Health Econ Health Policy. 2013 Jun;11(3):163-80
pubmed: 23529716
Asian Pac J Cancer Prev. 2015;16(8):3463-71
pubmed: 25921163
Ann Fam Med. 2013 Mar-Apr;11(2):106-15
pubmed: 23508596
BMJ. 2015 Mar 03;350:h980
pubmed: 25736617
Int J Surg. 2007 Apr;5(2):76-80
pubmed: 17448968
Prev Med. 2016 Oct;91:250-263
pubmed: 27527575
J Cancer Educ. 2011 Mar;26(1):156-60
pubmed: 21188664
J Gen Intern Med. 2006 Sep;21(9):979-85
pubmed: 16918745
Ont Health Technol Assess Ser. 2016 Jul 01;16(16):1-22
pubmed: 27468327
Psychooncology. 2013 Aug;22(8):1866-71
pubmed: 23203833
Psychooncology. 2019 May;28(5):939-947
pubmed: 30812068
J Clin Nurs. 2014 Jul;23(13-14):2053-62
pubmed: 24313329
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
JAMA Intern Med. 2014 Jun;174(6):954-61
pubmed: 24756610
AJR Am J Roentgenol. 2012 Oct;199(4):844-51
pubmed: 22997377
BMJ Open. 2016 Apr 06;6(4):e010723
pubmed: 27053274
Br J Cancer. 2014 Oct 28;111(9):1831-5
pubmed: 25167224
Breast. 2014 Dec;23(6):883-8
pubmed: 25456103
BMJ Open. 2013 Apr 22;3(4):
pubmed: 23610383
Women Health. 1996;24(4):47-67
pubmed: 9104764
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1388-97
pubmed: 26311562
BMC Geriatr. 2007 Nov 16;7:26
pubmed: 18021402
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
J Med Imaging Radiat Oncol. 2015 Jun;59(3):300-5
pubmed: 25900704
Radiology. 2006 Mar;238(3):793-800
pubmed: 16505392
Gac Sanit. 2011 Sep-Oct;25(5):357-62
pubmed: 21715064
Psychooncology. 2014 Apr;23(4):361-74
pubmed: 24677334
Lancet. 2012 Apr 14;379(9824):1390-1
pubmed: 22500874
J Cancer Educ. 2014 Mar;29(1):129-35
pubmed: 24092532
J Natl Cancer Inst. 2015 May 06;107(7):
pubmed: 25948872
PLoS Med. 2015 Oct 27;12(10):e1001895
pubmed: 26506244
Value Health. 2018 Feb;21(2):219-228
pubmed: 29477404
Evid Based Med. 2013 Apr;18(2):54-61
pubmed: 22859786
BMJ Open. 2017 Oct 6;7(10):e016894
pubmed: 28988175
Breast Cancer Res Treat. 2002 Dec;76(3):245-54
pubmed: 12462385
Breast. 2017 Feb;31:261-269
pubmed: 27717717
J Am Coll Radiol. 2013 Jun;10(6):423-31
pubmed: 23499400
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
J Clin Epidemiol. 2016 Aug;76:89-98
pubmed: 26931285
BMJ. 2013 Jan 23;346:f158
pubmed: 23344309
Psychooncology. 2017 Aug;26(8):1070-1079
pubmed: 27643482
Br J Surg. 2011 Apr;98(4):537-42
pubmed: 21656719
Psychooncology. 2010 Oct;19(10):1026-34
pubmed: 20882572

Auteurs

Alexander G Mathioudakis (AG)

Biomedical Research Institute (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Spain.
Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Minna Salakari (M)

Department of Public Health, Faculty of Medicine, University of Turku, Turku, Finland.

Liisa Pylkkanen (L)

Joint Research Centre, European Commission, Ispra, Italy.
Clinico-Pharmacological Unit, Finnish Medicines Agency Fimea, Turku, Finland.

Zuleika Saz-Parkinson (Z)

Joint Research Centre, European Commission, Ispra, Italy.

Anke Bramesfeld (A)

Joint Research Centre, European Commission, Ispra, Italy.
Institute for Epidemiology Social Medicine and Health System Research, Hanover Medical School, Hannover, Germany.

Silvia Deandrea (S)

Joint Research Centre, European Commission, Ispra, Italy.
Health Protection Agency, Metropolitan city of Milan, Italy.

Donata Lerda (D)

Joint Research Centre, European Commission, Ispra, Italy.

Luciana Neamtiu (L)

Joint Research Centre, European Commission, Ispra, Italy.

Hector Pardo-Hernandez (H)

Biomedical Research Institute (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Ivan Solà (I)

Biomedical Research Institute (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Pablo Alonso-Coello (P)

Biomedical Research Institute (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH